Literature DB >> 3105446

Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.

R Wise, B Kirkpatrick, J Ashby, D J Griggs.   

Abstract

A 400-mg dose of the trifluorinated quinolone Ro 23-6240 was administered orally to each of six healthy male volunteers, after which the concentrations of this agent in serum and cantharidin-induced inflammatory fluid were measured. Absorption was rapid, with a mean peak level in serum of 6.1 micrograms/ml, which was attained 0.71 h after administration. The elimination half-life in serum was 11.95 h. The agent penetrated the inflammatory fluid rapidly; the percent penetration was 89.7%. Urinary recovery of Ro 23-6240 was 58.6% by 72 h.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3105446      PMCID: PMC174683          DOI: 10.1128/AAC.31.2.161

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

Authors:  N Manek; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

3.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

4.  The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics.

Authors:  R Wise; A P Gillett; B Cadge; S R Durham; S Baker
Journal:  J Infect Dis       Date:  1980-07       Impact factor: 5.226

5.  Absorption, distribution, metabolic fate, and elimination of pefloxacin mesylate in mice, rats, dogs, monkeys, and humans.

Authors:  G Montay; Y Goueffon; F Roquet
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Norfloxacin disposition after sequentially increasing oral doses.

Authors:  B N Swanson; V K Boppana; P H Vlasses; H H Rotmensch; R K Ferguson
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

7.  Pharmacokinetics and tissue penetration of enoxacin.

Authors:  R Wise; R Lockley; J Dent; M Webberly
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  The pharmacokinetics and tissue penetration of ofloxacin.

Authors:  M R Lockley; R Wise; J Dent
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

9.  In vitro and in vivo antibacterial activity of AM-833, a new quinolone derivative.

Authors:  K Hirai; H Aoyama; M Hosaka; Y Oomori; Y Niwata; S Suzue; T Irikura
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

  9 in total
  27 in total

1.  Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.

Authors:  M J Wolfhagen; A I Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

2.  Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.

Authors:  T J Lubowski; C Nightingale; K Sweeney; R Quintiliani; J Zhi
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Renal handling of fleroxacin in rabbits, dogs, and humans.

Authors:  K Shiba; A Saito; J Shimada; S Hori; M Kaji; T Miyahara; H Kusajima; S Kaneko; S Saito; T Ooie
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

4.  Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies.

Authors:  B G Reigner; H A Welker
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Value of new quinolones in the treatment and prophylaxis of infectious diseases: introductory remarks.

Authors:  J S Wolfson; B E Murray
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

6.  Pharmacokinetics of a novel quinolone, AT-4140, in animals.

Authors:  S Nakamura; N Kurobe; T Ohue; M Hashimoto; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Tissue penetration and pharmacokinetics of lomefloxacin following multiple doses.

Authors:  J Kavi; J Stone; J M Andrews; J P Ashby; R Wise
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-02       Impact factor: 3.267

8.  Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.

Authors:  K Heim-Duthoy; G Peltier; W Awni
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.

Authors:  E Singlas; A Leroy; E Sultan; M Godin; B Moulin; A M Taburet; M Dhib; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

10.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.